Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
188Re-ethylenediamine tetramethylene phosphonate for painful bone metastases (phase II)
CTR20130708Phase 2Completed
- Sponsor
- Shanghai Institute of Applied Physics
- Start
- Aug 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Rhenium-188-HEDP in bone metastases, prostate cancer (PCa), breast cancer, bronchial carcinoma, sponsored by Shanghai Institute of Applied Physics. Started Aug 2017; status: completed.
02
Drugs
Rhenium-188-HEDP
03
Conditions
bone metastasesprostate cancer (PCa)breast cancerbronchial carcinoma
Beyond the preview
Go deeper on CTR20130708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130708.